A new randomised trial offers clearer evidence that a simple change to when people eat can lower testosterone and improve metabolic risk in those with polycystic ovary syndrome (PCOS). (take note that PCOS has been renamed to PMOS recently, during this transition period, both PCOS and PMOS would be used interchangeably)
The study, published in a leading medical journal Nature Medicine, compared two practical weight‑loss approaches over six months in premenopausal women with PCOS: time‑restricted eating (a daily six‑hour window) and conventional calorie counting.
“Time‑restricted eating decreased active androgen exposure and improved glycaemic markers without observable harms in the six‑month studied period”
The findings deserve attention because PCOS touches up to one in five women of reproductive age, and treatment options that avoid the drawbacks of long‑term hormonal medication are in demand.
PCOS is a complex endocrine condition. Excess androgens, chiefly testosterone, disturb menstrual cycles, fuel weight gain, and promote insulin resistance. Many patients are offered combined hormonal contraceptives as first‑line therapy.
These can control periods and lower circulating androgens. Yet hormonal therapy may produce adverse effects in some people: mood changes, altered libido, metabolic consequences and, in selected individuals, elevated cardiovascular risk. Non‑pharmacological strategies therefore remain important.
The trial enrolled 76 women with PCOS and randomised them to one of two dietary strategies for six months. One group practised time‑restricted eating, consuming all calories between 13:00 and 19:00 each day, with only water and calorie‑free drinks outside that window. The comparator group followed a standard calorie‑restriction plan designed to reduce daily energy intake by a similar amount.
“The time‑restricted group also demonstrated modest improvements in markers of glycaemic control, including haemoglobin A1c”
Both approaches reduced daily energy intake by roughly 200 kilocalories on average. Both produced weight loss — about 4.5 kg on average across the cohort over six months. That equivalence is important. It isolates effects of meal timing beyond the benefits obtained simply by losing weight.
Key hormone and metabolic outcomes diverged between the two strategies. Both groups experienced declines in circulating testosterone concentrations. However, only the time‑restricted eating group showed a statistically significant reduction in the free androgen index (FAI). FAI is the ratio of total testosterone to sex hormone‑binding globulin (SHBG). It approximates the fraction of biologically active, unbound androgen reaching tissues.
A fall in FAI therefore indicates reduced androgenic drive at the tissue level. The time‑restricted group also demonstrated modest improvements in markers of glycaemic control, including haemoglobin A1c. Calorie counting did not deliver the same pattern.
Those distinctions matter. In PCOS, the clinical manifestations—hirsutism, acne, irregular menses, infertility—reflect not just total testosterone, but how much active hormone is available to tissues.
A reduction in FAI may therefore translate into meaningful symptom relief. The trial did not, however, show improvements across every symptom domain within the six‑month follow‑up.
Menstrual irregularity, for example, did not change significantly in either arm. Investigators note that longer follow‑up and greater weight loss might be required to alter cycle patterns and reproductive outcomes.
Why might meal timing affect FAI and glycaemic markers differently from calorie reduction alone? Several plausible mechanisms exist. Time‑restricted eating aligns food intake with circadian rhythms, which regulate glucose metabolism, hormone secretion and energy balance.
Extended overnight fasting may increase insulin sensitivity and lower insulin exposure. Insulin suppresses hepatic production of SHBG; lower insulin levels permit higher SHBG. An increase in SHBG reduces the proportion of free, active testosterone, thereby lowering FAI even if total testosterone falls similarly in both groups.
Time‑restricted eating may also modulate appetite hormones, gut microbiome composition, and inflammatory signals. These pathways could amplify metabolic benefit independent of total weight loss.
Adherence and acceptability are vital in diet studies. In this trial, roughly four out of five participants in the time‑restricted eating group reported that they planned to continue the regimen beyond the study period. Ease of implementation was a common reason cited by investigators.
Time‑restricted eating requires no food‑type rules or frequent calorie calculations. It is, for many, a simpler behavioural change than meticulous calorie tracking. That simplicity can translate into sustained adherence and, ultimately, more durable improvements for patients.
The study was carefully designed, but not without limitations. Sample size was modest. The population was restricted to premenopausal women with PCOS; extrapolation to adolescents, perimenopausal women, or those with different ethnic or metabolic profiles should be cautious.
The six‑month horizon provides helpful short‑term data. Yet PCOS is a chronic condition. Whether the hormonal and metabolic benefits persist, enlarge, or fade over a longer duration remains to be seen. Menstrual function and fertility outcomes may need longer or larger studies to show meaningful change.
Safety concerns around intermittent fasting, particularly among women, have been voiced in recent years. Critics worry about potential disruptions to reproductive hormones or eating behaviour.
The present trial alleviates some of these fears in the PCOS population: time‑restricted eating decreased active androgen exposure and improved glycaemic markers without observable harms in the six‑month period. Still, clinicians should individualise recommendations. Those with a history of disordered eating, pregnancy, breastfeeding, or certain medical conditions require a distinct approach. Monitoring during implementation is prudent.
What does this mean for practice? For people with PCOS who are overweight or insulin resistant and seeking non‑pharmacological options, time‑restricted eating presents as a promising, low‑cost strategy.
Its principal advantages lie in simplicity and metabolic alignment: a fixed daily eating window that reduces total intake without complex meal planning. For clinicians, it offers an alternative or adjunct to calorie restriction.
When advising patients, emphasise that weight loss—about 5% of body weight—can reduce testosterone levels and improve metabolic risk markers. Time‑restricted eating appears to achieve this in a manner that may confer additional benefits on active androgen exposure and glycaemic control beyond calorie reduction alone.
Research implications are clear. Larger, multi‑centre trials should test the generalisability of these findings across different ages, ethnic groups, and severity of PCOS. Studies with extended follow‑up could determine whether the improvements in FAI and haemoglobin A1c persist and whether reproductive outcomes such as ovulation, cycle regularity, and fertility improve with continued practice. Mechanistic studies would help to quantify contributions from circadian biology, insulin dynamics, SHBG modulation, and inflammatory pathways. Finally, qualitative work should explore patient preferences, barriers and facilitators to sustained adherence.
Policymakers and guideline developers will take interest. Current PCOS guidance prioritises weight management and metabolic risk reduction. Time‑restricted eating, if corroborated by further trials, could be incorporated as a recommended behavioural option. It is inexpensive, scalable, and compatible with primary care delivery. Digital tools and remote coaching could further support implementation, particularly for patients who prefer a structured but flexible eating plan.
Patients considering time‑restricted eating should receive pragmatic advice. Aim for a consistent six‑hour window that suits daily life; late eating that encroaches on sleep may blunt the benefits. Maintain a balanced diet within the eating window—whole foods, adequate protein, fibre and vegetables—rather than using the approach to justify highly processed food choices. Stay hydrated between meals. Monitor for any adverse effects such as dizziness, excessive fatigue, or disordered eating thoughts. Seek medical advice if pregnant, breastfeeding, or on medications that require timing with food. Always talk to your healthcare providers for medical advice.
The trial adds to a growing literature indicating that when you eat may be as consequential as what you eat. For women with PCOS, a condition where androgen excess and insulin resistance intersect to drive symptoms and cardiometabolic risk, aligning intake to a daily six‑hour window offers a practical path to lower biologically active testosterone and improve glycaemic control, without the side effects associated with systemic hormonal therapy.
The evidence is not yet definitive. It is, however, compelling enough to prompt discussion between patients and their healthcare providers about whether time‑restricted eating might be an appropriate, low risk, and sustainable option in the broader toolbox for PCOS management.
The post Time-Restricted Eating in Women Helps with Polycystic Ovary Syndrome (PCOS) first appeared on PP Health Malaysia.
